Bart Maes

Novartis (Switzerland) — Switzerland

Medicine · Health Sciences

69h-index14.1kcitations354works14.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal Transplantation Outcomes and Treatments(58), Renal Diseases and Glomerulopathies(40), Organ Transplantation Techniques and Outcomes(24), Diet and metabolism studies(24), Chronic Kidney Disease and Diabetes(21)

Publications347 total

Iptacopan in Patients With IgA Nephropathy From East Asia
Kidney International Reports·2025Open Access
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
New England Journal of Medicine·2025· 11 cited
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
Nature Medicine·2025· 2 cited
#2936 Origin 3 study design: a global, randomized, controlled, Phase 3 study of atacicept in IgA nephropathy
Nephrology Dialysis Transplantation·2025
#2859 <b>ORIGIN 2b: changes in Gd-IgA1 and eGFR after discontinuation of atacicept treatment in IgA nephropathy</b>
Nephrology Dialysis Transplantation·2025Open Access
ORIGIN 3: A Phase 3 Trial of Atacicept in IgAN
Journal of the American Society of Nephrology·2025
#2808 A mechanistic biopsy study of the effect of iptacopan on immunopathology in patients with IgA nephropathy (IgAN)
Nephrology Dialysis Transplantation·2025Open Access
#2626 Effect of iptacopan discontinuation on proteinuria and complement biomarkers in patients with immunoglobulin A nephropathy (IgAN): a post hoc analysis from a Phase II trial
Nephrology Dialysis Transplantation·2025Open Access
Biomarker Insights from the Phase 3 APPLAUSE-IgAN Study: Iptacopan's Proteomic Signature in IgAN
Journal of the American Society of Nephrology·2025
Timekeeping precision enhancements at constant power
ArXiv.org·2025Open Access
Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression
Clinical Journal of the American Society of Nephrology·2025· 2 citedOpen Access
The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency
Clinical Kidney Journal·2025· 2 citedOpen Access
WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
Kidney International Reports·2025Open Access
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
Journal of the American Society of Nephrology·2024· 38 citedOpen Access
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
New England Journal of Medicine·2024· 119 cited
Long-Term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgA Nephropathy (IgAN)
Journal of the American Society of Nephrology·2024· 2 cited
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Nephrology Dialysis Transplantation·2024· 62 citedOpen Access
#123 Impact of atacicept on hematuria in IGA nephropathy: post-hoc analysis of the phase 2b ORIGIN study
Nephrology Dialysis Transplantation·2024· 2 citedOpen Access
#812 Phase 2b ORIGIN study open label extension with atacicept in patients with IgA nephropathy and persistent proteinuria: week 72 interim analysis
Nephrology Dialysis Transplantation·2024· 4 citedOpen Access
WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY
Kidney International Reports·2024· 1 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Yves Vanrenterghem(11), Pieter Evenepoel(10), Jonathan Barratt(9), Hallvard Holdaas(8), Alan G. Jardine(8), Dirk Kuypers(8), Yvo Ghoos(7), Benny Geypens(7), Bengt Fellström(7), Edward Cole(7), Jürgen Floege(7), Carola Grönhagen‐Riska(6), Hans‐Hellmut Neumayer(6), Manuel Praga(6), Lucia Del Vecchio(6), Hiddo J.L. Heerspink(6), Vlado Perkovic(6), Brad H. Rovin(6), Hernán Trimarchi(6), Martin Hiele(5)